Equity Profile

ILMN

Illumina, Inc.

Health CareLife Sciences Tools & Services$24.6B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Illumina, Inc. is a leader in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will signal how well the company is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product offerings, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ILMN Q2-2026 Earnings Preview

Context

Company Snapshot

Illumina, Inc. is a leader in the health care sector, specializing in life sciences tools and services. The company plays a crucial role in genetic sequencing and analysis, which is increasingly important in personalized medicine and diagnostics.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In Q1-2026, Illumina reported an EPS of $1.15, exceeding expectations by 9.73%. The stock reacted positively, gaining 5.29% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Illumina's upcoming earnings, given its strong track record of beating EPS estimates. However, there is uncertainty regarding revenue figures and overall market conditions.

Bull Case

If Illumina continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Illumina's consistent history of beating EPS estimates, this number will be critical in determining market sentiment post-earnings.

How is revenue growth trending compared to previous quarters?

Investors will closely watch revenue growth to assess the company's market position and demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Illumina's ability to leverage its technology for new product offerings, which could drive unexpected revenue growth.

Supporting Evidence

Illumina has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a significant move, suggesting traders expect volatility that may not align with consensus.

Recent insider buying could signal confidence in the company's future performance.

Key Risk

If revenue growth exceeds expectations, it could invalidate the cautious outlook currently held by the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Illumina can maintain its growth momentum in a competitive landscape, making these earnings critical.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.05 would raise concerns about the company's growth trajectory and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±19.18%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±19.2% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

41.8%

Calls (160K)P/C Ratio: 0.12Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats expectations, history suggests the stock could rise by around 1.42% on the following day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but cautious on guidance, the stock may see muted movement as investors reassess growth prospects.

Miss

A miss could lead to a decline, with historical data suggesting a potential drop of around 2.83% based on past performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or technological advancements.
2Details on market demand for genetic sequencing services.
3Insights into competitive pressures and how Illumina plans to address them.
4Management's outlook on revenue growth for the upcoming quarters.
5Any commentary on cost management and gross margin expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Illumina, Inc. is a leader in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will signal how well the company is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product offerings, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ILMN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In Q1-2026, Illumina reported an EPS of $1.15, exceeding expectations by 9.73%. The stock reacted positively, gaining 5.29% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Illumina continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Illumina's consistent history of beating EPS estimates, this number will be critical in determining market sentiment post-earnings.

How is revenue growth trending compared to previous quarters?

Investors will closely watch revenue growth to assess the company's market position and demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Illumina's ability to leverage its technology for new product offerings, which could drive unexpected revenue growth.

Supporting Evidence

Illumina has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a significant move, suggesting traders expect volatility that may not align with consensus.

Recent insider buying could signal confidence in the company's future performance.

Key Risk

If revenue growth exceeds expectations, it could invalidate the cautious outlook currently held by the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Illumina can maintain its growth momentum in a competitive landscape, making these earnings critical.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.05 would raise concerns about the company's growth trajectory and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±19.18%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±19.2% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

41.8%

Calls (160K)P/C Ratio: 0.12Puts (26K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats expectations, history suggests the stock could rise by around 1.42% on the following day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but cautious on guidance, the stock may see muted movement as investors reassess growth prospects.

Miss

A miss could lead to a decline, with historical data suggesting a potential drop of around 2.83% based on past performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or technological advancements.
2Details on market demand for genetic sequencing services.
3Insights into competitive pressures and how Illumina plans to address them.
4Management's outlook on revenue growth for the upcoming quarters.
5Any commentary on cost management and gross margin expectations.